Olympiad Research LP Takes Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Olympiad Research LP bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,162 shares of the medical equipment provider’s stock, valued at approximately $228,000.

Several other institutional investors also recently added to or reduced their stakes in ZBH. Roman Butler Fullerton & Co. acquired a new stake in Zimmer Biomet in the 4th quarter worth $473,000. Geode Capital Management LLC grew its position in Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp raised its stake in Zimmer Biomet by 48.4% during the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after acquiring an additional 8,709 shares in the last quarter. KLCM Advisors Inc. bought a new position in shares of Zimmer Biomet during the fourth quarter valued at $7,825,000. Finally, Peddock Capital Advisors LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $654,000. 88.89% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

ZBH has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Stifel Nicolaus raised their price target on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a report on Thursday, January 23rd. Truist Financial restated a “hold” rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a report on Monday, February 10th. JMP Securities reiterated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, Raymond James decreased their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

Zimmer Biomet stock opened at $104.89 on Monday. The company has a market cap of $20.88 billion, a PE ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The company’s 50-day moving average is $105.86 and its two-hundred day moving average is $107.46. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the business posted $2.20 EPS. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, January 31st. Stockholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.